nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2021-6-147-152nnp-1721Research ArticleINFORMATIONИНФОРМАЦИЯPost-release of the symposium «How to Deal with Pain in the 21st Century? Expert Opinions» (November 8, 2021, XII Interdisciplinary International Congress «Manage Pain»)Пост-релиз симпозиума «Как обыграть боль в 21 веке? Мнения экспертов» (8 ноября 2021 г., XII Междисциплинарный международный конгресс «Manage Pain»)https://orcid.org/0000-0003-1499-247XОстроумоваТ. М.OstroumovaT. M.

 кафедра нервных болезней и нейрохирургии

t.ostroumova3@gmail.comИнститут клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет) Russian Federation202116122021136147152Copyright © Ostroumova T.M., 20212021Остроумова Т.М.Ostroumova T.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1721

The article presents the chronology of the symposium «How to Deal with Pain in the 21st Century? Experts' opinions», which took place on November 8 during the XII interdisciplinary international congress «Manage Pain». The lectures discussed issues of non-steroidal anti-inflammatory drugs (NSAIDs), including etoricoxib (Atorika tabs), administration on the example of a clinical case, problems of terminology associated with the concepts of «lumbago» and «sciatica», rare clinical syndromes (for example, heavy-purse syndrome) that we need to differentiate nonspecific back pain with, strategies for choosing NSAIDs in patients with osteoarthritis, the importance of timely administration of NSAIDs in the prevention of chronic pain syndromes, the influence of emotional and cognitive factors on the back pain chronization. The benefits of etoricoxib (Atorika) in the treatment of chronic back pain were reviewed, as well as the evidence for its safety.

В статье представлена хронология симпозиума «Как обыграть боль в 21 веке? Мнения экспертов», прошедшего 8 ноября 2021 г. в рамках XII Междисциплинарного международного конгресса «Manage Pain» («Управляй болью!»). На симпозиуме обсуждались вопросы назначения нестероидных противовоспалительных препаратов (НПВП), в том числе эторикоксиба (Аторика табс), на примере клинического случая, проблемы терминологии, связанные с понятиями «люмбаго» и «ишиас», редкие клинические синдромы (например, синдром толстого кошелька), с которыми необходимо дифференцировать неспецифические боли в спине, стратегии выбора НПВП у пациентов с остеоартритом, важность своевременного назначения НПВП в рамках профилактики хронизации болевых синдромов, влияние эмоциональных и когнитивных факторов на хронизацию боли в спине. Обсуждалось использование эторикоксиба (Аторика) в лечении хронической боли в спине, а также данные о его безопасности.

manage painнестероидные противовоспалительные препаратыселективные ингибиторы циклооксигеназы-2эторикоксибАторика табсmanage painnon-steroidal anti-inflammatory drugsselective COX-2 inhibitorsetoricoxibAtorika tabsReferencesLin HY, Cheng TT, Wang JH, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010 May;13(2):144-50. doi: 10.1111/j.1756-185X.2010.01468.xLin HY, Cheng TT, Wang JH, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010 May;13(2):144-50. doi: 10.1111/j.1756-185X.2010.01468.xArendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-44. doi: 10.1097/j.pain.0000000000000562Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-44. doi: 10.1097/j.pain.0000000000000562Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017 Nov;25(11):1781-91. doi: 10.1016/j.joca.2017.07.009Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017 Nov;25(11):1781-91. doi: 10.1016/j.joca.2017.07.009Urits I, Burshtein A, Sharma M, et al. Low back pain, a comprehensive review: pathophysiology, diagnosis, and treatment. Curr Pain Headache Rep. 2019 Mar;23(3):23. doi: 10.1007/s11916-019-0757-1Urits I, Burshtein A, Sharma M, et al. Low back pain, a comprehensive review: pathophysiology, diagnosis, and treatment. Curr Pain Headache Rep. 2019 Mar;23(3):23. doi: 10.1007/s11916-019-0757-1Парфенов ВА, Яхно НН, Кукушкин МЛ и др. Острая неспецифическая (скелетномышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2018;10(2):4-11. doi: 10.14412/2074-2711-2018-2-4-11Parfenov VA, Yakhno NN, Kukushkin ML, et al. Acute nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):4-11. doi: 10.14412/2074-2711-2018-2-4-11 (In Russ.).Парфенов ВА, Яхно НН, Давыдов ОС и др. Хроническая неспецифическая (скелетно-мышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2019;11(2S):7-16. doi: 10.14412/2074-2711-2019-2S-7-16Parfenov VA, Yakhno NN, Davydov OS, et al. Chronic nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2S):7-16. doi: 10.14412/2074-2711-2019-2S-7-16 (In Russ.).Kalichman L, Kim DH, Li L, et al. Computed tomography-evaluated features of spinal degeneration: prevalence, intercorrelation, and association with self-reported low back pain. Spine J. 2010 Mar;10(3):200-8. doi: 10.1016/j.spinee.2009.10.018Kalichman L, Kim DH, Li L, et al. Computed tomography-evaluated features of spinal degeneration: prevalence, intercorrelation, and association with self-reported low back pain. Spine J. 2010 Mar;10(3):200-8. doi: 10.1016/j.spinee.2009.10.018Cohen SP, Chen Y, Neufeld NJ. Sacroiliac joint pain: a comprehensive review of epidemiology, diagnosis and treatment. Expert Rev Neurother. 2013 Jan;13(1):99-116. doi: 10.1586/ern.12.148Cohen SP, Chen Y, Neufeld NJ. Sacroiliac joint pain: a comprehensive review of epidemiology, diagnosis and treatment. Expert Rev Neurother. 2013 Jan;13(1):99-116. doi: 10.1586/ern.12.148Vardeh D, Mannion RJ, Woolf CJ. Toward a Mechanism-Based Approach to Pain Diagnosis. J Pain. 2016 Sep;17(9 Suppl):T50-69. doi: 10.1016/j.jpain.2016.03.001Vardeh D, Mannion RJ, Woolf CJ. Toward a Mechanism-Based Approach to Pain Diagnosis. J Pain. 2016 Sep;17(9 Suppl):T50-69. doi: 10.1016/j.jpain.2016.03.001Siddiq MAB, Rahim MA, Khan MTI, Shikder AZH. Lumbar Ligament Sprain-degeneration and Prolapsed Lumbar Intervertebral Disc: A Frequent Missed Combination. Cureus. 2019 Jan 25;11(1):e3958. doi: 10.7759/cureus.3958Siddiq MAB, Rahim MA, Khan MTI, Shikder AZH. Lumbar Ligament Sprain-degeneration and Prolapsed Lumbar Intervertebral Disc: A Frequent Missed Combination. Cureus. 2019 Jan 25;11(1):e3958. doi: 10.7759/cureus.3958Филатова ЕС, Туровская ЕФ, Алексеева ЛИ и др. Анализ патогенетических механизмов хронической суставной боли у больных ревматоидным артритом и остеоартрозом коленных суставов. Научно-практическая ревматология. 2014;52(6):631-5. doi: 10.14412/1995-4484-2014-631-635Filatova ES, Turovskaya EF, Alekseeva LI, et al. Analysis of the pathogenetic mechanisms of chronic joint pain in patients with rheumatoid arthritis and knee osteoarthritis. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):631-5. doi: 10.14412/1995-4484-2014-631-635 (In Russ.).Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56(Прил. 1):1-29. doi: 10.14412/1995-4484-2018-1-29Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(Suppl 1):1-29. doi: 10.14412/1995-4484-2018-1-29 (In Russ.).Каратеев АЕ. Эторикоксиб может использоваться при хронической неспецифической боли в спине: новое показание для хорошо известного препарата. Неврология, нейропсихиатрия, психосоматика. 2020;12(2):125-30. doi: 10.14412/2074-2711-2020-2-125-130Karateev AE. Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(2):125-30. doi: 10.14412/2074-2711-2020-2-125-130 (In Russ.).Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo- controlled, 3-month trial. J Pain. 2003 Aug;4(6):307-15. doi: 10.1016/s1526-5900(03)00633-3Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo- controlled, 3-month trial. J Pain. 2003 Aug;4(6):307-15. doi: 10.1016/s1526-5900(03)00633-3Pallay RM, Seger W, Adler JL, et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33(4):257-66. doi: 10.1080/03009740410005728Pallay RM, Seger W, Adler JL, et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33(4):257-66. doi: 10.1080/03009740410005728Zerbini C, Ozturk Z, Grifka J, et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin. 2005 Dec;21(12):2037-49. doi: 10.1185/030079905X75069Zerbini C, Ozturk Z, Grifka J, et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin. 2005 Dec;21(12):2037-49. doi: 10.1185/030079905X75069Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov;368(9549):1771-81. doi: 10.1016/S0140-6736(06)69666-9Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov;368(9549):1771-81. doi: 10.1016/S0140-6736(06)69666-9Van der Gaag WH, Roelofs PD, Enthoven WT, et al. Non-steroidal anti-inflammatory drugs for acute low back pain. Cochrane Database Syst Rev. 2020 Apr;4:CD013581. doi: 10.1002/14651858.CD013581Van der Gaag WH, Roelofs PD, Enthoven WT, et al. Non-steroidal anti-inflammatory drugs for acute low back pain. Cochrane Database Syst Rev. 2020 Apr;4:CD013581. doi: 10.1002/14651858.CD013581Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal antiinflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network metaanalysis. Lancet. 2017;390(10090):e21-e33. doi: 10.1016/S0140-6736(17)31744-0Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal antiinflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network metaanalysis. Lancet. 2017;390(10090):e21-e33. doi: 10.1016/S0140-6736(17)31744-0Watson DJ, Bolognese JA, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin. 2004 Dec;20(12):1899-908. doi: 10.1185/030079904X12681Watson DJ, Bolognese JA, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin. 2004 Dec;20(12):1899-908. doi: 10.1185/030079904X12681Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011 Jan;342:c7086. doi: 10.1136/bmj.c7086Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011 Jan;342:c7086. doi: 10.1136/bmj.c7086GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7Corder G, Ahanonu B, Grewe BF, et al. An amygdalar neural ensemble that encodes the unpleasantness of pain. Science. 2019 Jan;363(6424):276-81. doi: 10.1126/science.aap8586Corder G, Ahanonu B, Grewe BF, et al. An amygdalar neural ensemble that encodes the unpleasantness of pain. Science. 2019 Jan;363(6424):276-81. doi: 10.1126/science.aap8586

The authors declare that there are no conflicts of interest present.